• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Comprehensive immunological analysis of macrophage activation syndrome

Research Project

Project/Area Number 19K17354
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 52050:Embryonic medicine and pediatrics-related
Research InstitutionKanazawa University

Principal Investigator

Inoue Natsumi  金沢大学, 医学系, 協力研究員 (90808924)

Project Period (FY) 2019-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywordsマクロファージ活性化症候群 / 小児リウマチ性疾患 / サイトカイン / バイオマーカー
Outline of Research at the Start

マクロファージ活性化症候群(Macrophage activation syndrome:MAS)の病態には、免疫細胞の異常活性化とサイトカインの過剰産生が深く関与している。本研究では、末梢血細胞亜群解析、サイトカインアレイ解析、末梢血単核球mRNAに対するmicroarray解析を組み合わせた網羅的な免疫学的解析を行い、MASの基礎病態を理解するとともに、基礎疾患によるMASの免疫学的異常の異同を明らかにし、MAS病態に深く関与する共通の分子に対する特異的治療法の開発を目指す。

Outline of Final Research Achievements

We defined cytokine profiles of MAS complicated with various pediatric rheumatic diseases comparing the profiles between acute phase and MAS phase. Common pattern among MAS (elevation of neopterin, sTNFR-II and IL-18) was revealed and these would be candidates of biomarkers for predicting MAS in early phase and molecular target for treatment. On the other hand, the best marker for distinguishing MAS was different in each background diseases. These findings suggests treatment strategy should be considered individually even though clinical phenotype is similar.

Academic Significance and Societal Importance of the Research Achievements

本研究により、さまざまなリウマチ性疾患を背景として発症するMASの病態に共通して関与する・あるいは各疾患によって異なるサイトカインプロファイルの特徴が明らかになった。未だ臨床試験段階である抗IFNγ療法など、ターゲットを絞った治療法の有効性を支持する一助となる。また臨床像は共通するものの背景疾患により異なる基礎病態が示唆されたことで、治療戦略には疾患ごとに工夫が必要であることも併せて明らかになった。

Report

(4 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • 2019 Research-status Report
  • Research Products

    (3 results)

All 2020 2019

All Journal Article (2 results) (of which Peer Reviewed: 2 results) Presentation (1 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children2020

    • Author(s)
      Mizuta Mao、Shimizu Masaki、Irabu Hitoshi、Usami Masaaki、Inoue Natsumi、Nakagishi Yasuo、Wada Taizo、Yachie Akihiro
    • Journal Title

      Rheumatology

      Volume: 60 Issue: 1 Pages: 231-238

    • DOI

      10.1093/rheumatology/keaa299

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Extensive serum biomarker analysis in patients with macrophage activation syndrome associated with systemic lupus erythematosus.2019

    • Author(s)
      Usami M, Shimizu M, Mizuta M, Inoue N, Irabu H, Sakumura N, Nakagishi Y, Yachie A.
    • Journal Title

      Clinical Immunology

      Volume: 208 Pages: 108255-108255

    • DOI

      10.1016/j.clim.2019.108255

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Presentation] COMPARISON OF SERUM CYTOKINE PROFILE IN MACROPHAGE ACTIVATION SYNDROME AMONG DIFFERENT BACKGROUND RHEUMATIC DISEASES IN CHILDREN2019

    • Author(s)
      Mao Mizuta, Masaki Shimizu, Masaaki Usami, Naoto Sakumura, Hitoshi Irabu, Maiko Takakuwa, Natsumi Inoue, Yasuo Nakagishi, Akihiro Yachie
    • Organizer
      EULAR 2019
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2019-04-18   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi